The Fort Worth Press - FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

USD -
AED 3.672501
AFN 63.999821
ALL 82.253977
AMD 360.510128
ANG 1.790403
AOA 917.498737
ARS 1552.758602
AUD 1.483977
AWG 1.8025
AZN 1.699803
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.796998
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.429745
CDF 2317.999928
CHF 0.841035
CLF 0.02537
CLP 998.480068
CNY 6.66455
CNH 6.666355
COP 3314.81
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.18105
DJF 178.098271
DKK 6.79992
DOP 60.559465
DZD 137.08899
EGP 53.689599
ERN 15
ETB 164.140883
EUR 0.90965
FJD 2.296797
FKP 0.758367
GBP 0.75805
GEL 2.595013
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.502912
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 333.008502
IDR 18270.5
ILS 3.24803
IMP 0.758367
INR 93.48355
IQD 1516.079284
IRR 1925253.999459
ISK 124.44977
JEP 0.758367
JMD 158.919789
JOD 0.708989
JPY 159.399503
KES 129.999947
KGS 87.449019
KHR 4080.072793
KMF 447.497235
KPW 900.00035
KRW 1336.402706
KWD 0.31172
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 56.069019
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.859893
MVR 15.409893
MWK 1734.212921
MXN 18.486875
MYR 4.094503
MZN 63.910141
NAD 16.918528
NGN 1349.369821
NIO 36.80602
NOK 9.625225
NPR 149.481136
NZD 1.81936
OMR 0.384508
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.6585
PKR 276.505202
PLN 4.00316
PYG 6230.864068
QAR 3.64562
RON 4.865802
RSD 107.022012
RUB 82.04668
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.879028
SDG 601.49862
SEK 10.126925
SGD 1.288895
SHP 0.758581
SLE 23.050416
SLL 20969.503664
SOS 571.501363
SRD 37.43798
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.834502
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.417602
TTD 6.771395
TWD 32.941978
TZS 2650.003004
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603604
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 596.691317
XAG 0.02097
XAU 0.000259128447
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 596.691317
XPF 108.509428
YER 236.503383
ZAR 16.94351
ZMK 9001.198726
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.073939
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae

Crofelemer previously granted orphan-drug designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome and microvillus inclusion disease

Text size:

World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae

Crofelemer previously granted orphan-drug designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome and microvillus inclusion disease

Jaguar Health(NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to crofelemer, the company's novel plant-based prescription drug, for treatment of diarrhea in cholera.

"We are very pleased that crofelemer has been granted orphan-drug designation for this important indication," said Steven King, PhD, Jaguar's Chief Sustainable Supply, Ethnobotanical Research & IP Officer. "The company previously presented Phase 2 data on crofelemer for the treatment of devastating dehydration in cholera patients from the renowned International Centre for Diarrhoeal Disease Research (icddr,b) in Bangladesh. Receipt of orphan drug designation qualifies the company for various development incentives, including tax credits for qualified clinical testing and relief of filing fees, and provides the company with a seven-year period of marketing exclusivity if marketing approval is approved for crofelemer for this indication in the U.S. We expect to pursue ODD for crofelemer for this indication from the EMA as well in the future."

Due to the very low incidence and prevalence of cholera in the United States, cholera is an orphan indication in this country. Crofelemer is also the subject of five other rare/orphan disease-related clinical efforts - three investigator-initiated trial (IIT) proof-of-concept studies and two Phase 2 studies - for the indications of short bowel syndrome with intestinal failure (SBS-IF) and/or microvillus inclusion disease (MVID) in the US, European Union, and/or Middle East/North Africa regions. Dosing of the first patient in each of these five studies is expected to occur throughout December 2024 and Q1 2025, with availability of IIT proof-of-concept results potentially in Q2 2025. In accordance with the guidelines of specific EU countries, published data from clinical investigations in SBS-IF and MVID could support reimbursed early patient access to crofelemer for these debilitating conditions in those countries.

Crofelemer has also been granted ODD by the FDA and the EMA for both MVID and SBS.

Additionally, Jaguar intends to pursue orphan-drug designation and a Tropical Disease Priority Review Voucher for the indication of treatment of diarrhea in cholera with a proprietary second-generation anti-secretory agent, NP-300, which, like crofelemer, is sustainably derived from the Croton lechleri tree. Priority review vouchers are transferable, and in past transactions by other companies have sold for values ranging from $67 million to $350 million, which provides for a potential immediate return on investment upon approval of NP-300 for the indication of treatment of diarrhea in cholera.

Although cholera is an orphan indication in the U.S., it is estimated that, worldwide, 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year, according to the Centers for Disease Control and Prevention of the U.S. Department of Health & Human Services.1 Approximately one in 10 infected persons will have severe disease characterized by profuse watery diarrhea, vomiting, and leg cramps. In these people, rapid loss of body fluids leads to dehydration and shock. Without treatment, death can occur within hours. Cholera is now endemic in many countries outside the U.S. From January 1, 2024 to July 28, 2024, a cumulative total of 307,433 cholera cases and 2,326 deaths were reported from 26 countries across five World Health Organization (WHO) regions.2 WHO classified the global resurgence of cholera as a grade 3 emergency in January 2023, the highest internal level for emergencies in WHO.2 Based on the number of outbreaks and their geographic expansion, alongside the shortage of vaccines and other resources, WHO continues to assess the risk at the global level as very high and the event remains classified as a grade 3 emergency.2

About Orphan-Drug Designation in the US and European Union

The Orphan Drug Act in the U.S. provides for granting special status to a small molecule drug or biological product to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan-drug designation (or sometimes "orphan status"). In the EU, receipt of ODD supports some specific regulatory pathways, and sponsors who obtain ODD for their drug can benefit from Scientific Advice from the EMA for clinical trials for the orphan indication and receive market exclusivity for a period of ten years once the medicine is approved for commercialization.

About Crofelemer

Crofelemer is a botanical (plant-based) drug extracted and purified from the red bark sap, also referred to as "dragon's blood," of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company will pursue ODD for crofelemer for treatment of diarrhea in cholera from the EMA in the future, Jaguar's expectation that dosing of the first patient in each of three IITs and two Phase 2 studies of crofelemer for SBS-IF and/or MVID will occur throughout December 2024 and Q1 2025, Jaguar's expectation that IIT proof-of-concept results for crofelemer for SBS-IF and/or MVID could potentially be available in Q2 2025, Jaguar's expectation that, in accordance with the guidelines of specific EU countries, published data from clinical investigations in SBS-IF and MVID could support reimbursed early patient access to crofelemer for these debilitating conditions in those countries, Jaguar's expectation that it will also pursue the indication of treatment of diarrhea in cholera with NP-300, Jaguar's expectation that it will pursue orphan-drug designation for NP-300 for treatment of diarrhea in cholera, and Jaguar's expectation that NP-300 may qualify for a Tropical Disease Priority Review Voucher if NP-300 is approved by the FDA for treatment of diarrhea in cholera. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

1https://www.cdc.gov/cholera/about/index.html#:~:text=Most%20people%20who%20get%20cholera,ill%20patients%20can%20survive%20cholera

2https://www.who.int/publications/m/item/multi-country-outbreak-of-cholera--external-situation-report--17---15-august-2024

Contact:

[email protected]
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

S.Jones--TFWP